Get our latest issue now

available for iOS, Android & web

latest issue

Novartis' Afinitor gets breast cancer green light in EU

Daily News | July 30, 2012

Kevin Grogan

Novartis' Afinitor gets breast cancer green light in EU

After getting the thumbs-up in the USA last week, Novartis' Afinitor has now been approved in Europe as a treatment for advanced breast cancer.

The European Commission has approved Afinitor (everolimus) for use in combination with Pfizer's Aromasin (exemestane) to treat certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer. Specifically, the combo is intended for use in women with recurrence or progression of their cancer after treatment with a non-steroidal aromatase inhibitor.

Herve Hoppenot, Novartis Oncology president, said the approval of Afinitor is "an important milestone marking the first major advance for women in the European Union with hormone receptor-positive advanced breast cancer since the introduction of aromatase inhibitors more than 15 years ago". The company quoted Jose Baselga of the Massachusetts General Hospital who said that "by boosting the effectiveness of endocrine therapy, Afinitor significantly extends the time women with hormone receptor-positive advanced breast cancer live without tumour progression".

He added that the drug, the first mTOR inhibitor to be approved for this disease, "has the potential to redefine the way this common form of advanced breast cancer is treated". Afinitor is already approved in Europe for advanced renal cell carcinoma and for progressive advanced neuroendocrine tumours of pancreatic origin; second-quarter sales rose 72% to $175 million.

Click here to order a reprint of this news story.


Your Comments

Tell us what you think.

Twitter Go to @PharmaTimes

Find a job

Website Search

Search News Search Magazine

Business Insight


Competitions News


International Clinical Researcher of the Year 2016

Book your tickets today!